These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29463509)

  • 1. Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry.
    Friedman DJ; Parzynski CS; Heist EK; Russo AM; Akar JG; Freeman JV; Curtis JP; Al-Khatib SM
    Circulation; 2018 Jun; 137(23):2463-2477. PubMed ID: 29463509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraoperative Defibrillation Testing of Subcutaneous Implantable Cardioverter-Defibrillator Systems-A Simple Issue?
    Frommeyer G; Zumhagen S; Dechering DG; Larbig R; Bettin M; Löher A; Köbe J; Reinke F; Eckardt L
    J Am Heart Assoc; 2016 Mar; 5(3):e003181. PubMed ID: 27068637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defibrillators: Selecting the Right Device for the Right Patient.
    Al-Khatib SM; Friedman P; Ellenbogen KA
    Circulation; 2016 Nov; 134(18):1390-1404. PubMed ID: 27799257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.
    Maurizi N; Tanini I; Olivotto I; Amendola E; Limongelli G; Losi MA; Allocca G; Perego GB; Pieragnoli P; Ricciardi G; De Filippo P; Ferrari P; Quarta G; Viani S; Rapacciuolo A; Bongiorni MG; Cecchi F
    Int J Cardiol; 2017 Mar; 231():115-119. PubMed ID: 28073660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: data from the Israeli ICD Registry.
    Arnson Y; Suleiman M; Glikson M; Sela R; Geist M; Amit G; Schliamser JE; Goldenberg I; Ben-Zvi S; Orvin K; Rosenheck S; Adam Freedberg N; Strasberg B; Haim M
    Heart Rhythm; 2014 May; 11(5):814-21. PubMed ID: 24486799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States.
    Friedman DJ; Parzynski CS; Varosy PD; Prutkin JM; Patton KK; Mithani A; Russo AM; Curtis JP; Al-Khatib SM
    JAMA Cardiol; 2016 Nov; 1(8):900-911. PubMed ID: 27603935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success.
    Amin AK; Gold MR; Burke MC; Knight BP; Rajjoub MR; Duffy E; Husby M; Stahl WK; Weiss R
    Circ Arrhythm Electrophysiol; 2019 Apr; 12(4):e006665. PubMed ID: 30917689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful defibrillation verification in subcutaneous implantable cardioverter-defibrillator recipients by low-energy shocks.
    Biffi M; Ziacchi M; Angeletti A; Castelli A; Massaro G; Martignani C; Lovecchio M; Valsecchi S; Diemberger I
    Clin Cardiol; 2019 Jun; 42(6):612-617. PubMed ID: 30989668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE).
    Healey JS; Hohnloser SH; Glikson M; Neuzner J; Mabo P; Vinolas X; Kautzner J; O'Hara G; VanErven L; Gadler F; Pogue J; Appl U; Gilkerson J; Pochet T; Stein KM; Merkely B; Chrolavicius S; Meeks B; Foldesi C; Thibault B; Connolly SJ;
    Lancet; 2015 Feb; 385(9970):785-91. PubMed ID: 25715991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is 40 Joules Enough to Successfully Defibrillate With Subcutaneous Implantable Cardioverter-Defibrillators?
    Biffi M; Bongiorni MG; D'Onofrio A; Manzo M; Pieragnoli P; Palmisano P; Ottaviano L; Perego GB; Pangallo A; Lavalle C; Bonfantino V; Nigro G; Landolina ME; Katsouras G; Diemberger I; Viani S; Bianchi V; Lovecchio M; Valsecchi S; Ziacchi M;
    JACC Clin Electrophysiol; 2021 Jun; 7(6):767-776. PubMed ID: 33516714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of a high defibrillation threshold test during routine ICD implantation.
    Al-Atia B; Vandenberk B; Vörös G; Garweg C; Ector J; Willems R
    Acta Cardiol; 2018 Jun; 73(3):267-273. PubMed ID: 28885097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable Cardioverter Defibrillator Implantation with or Without Defibrillation Testing.
    Duffett S; El Hajjaji I; Manlucu J; Yee R
    Card Electrophysiol Clin; 2018 Mar; 10(1):119-125. PubMed ID: 29428133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Patients Undergoing Long-Term Dialysis.
    Pun PH; Parzynski CS; Friedman DJ; Sanders G; Curtis JP; Al-Khatib SM
    Clin J Am Soc Nephrol; 2020 Nov; 15(11):1622-1630. PubMed ID: 32967922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procedure timing as a predictor of inhospital adverse outcomes from implantable cardioverter-defibrillator implantation: insights from the National Cardiovascular Data Registry.
    Hsu JC; Varosy PD; Parzynski CS; Chaudhry SI; Dewland TA; Curtis JP; Marcus GM
    Am Heart J; 2015 Jan; 169(1):45-52.e3. PubMed ID: 25497247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.